TOP TEN perturbations for 40054_at (Homo sapiens)
Organism: Homo sapiens
Gene: 40054_at
Selected probe(set): 212380_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 40054_at (212380_at) across 6674 perturbations tested by GENEVESTIGATOR:
IFN-a2b study 1 / untreated immature dendritic cell sample
Relative Expression (log2-ratio):1.950531Number of Samples:3 / 3
Experimental | IFN-a2b study 1 |
Immature dendritic cells (DCs) treated with 1000 U/ml of IFN-a2b. | |
Control | untreated immature dendritic cell sample |
Immature dendritic cells (DCs) without IFN alpha treatment. |
glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):1.9403Number of Samples:2 / 4
Experimental | glioma study 17 (glioblastoma; unsorted) |
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. | |
Control | non-tumor cortical tissue |
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample
Relative Expression (log2-ratio):1.8782654Number of Samples:4 / 4
Experimental | B-CLL study 11 (DMSO) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
Control | vehicle (DMSO) treated normal B-cell sample |
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
interferon-alpha study 1 / untreated whole blood sample
Relative Expression (log2-ratio):1.7424603Number of Samples:9 / 43
Experimental | interferon-alpha study 1 |
Whole blood samples treated in vitro with 3xEC50/ml of IFNa-mix (containing all 13 different subtypes of IFNa) for 4 hours in prefilled Na-heparin tubes with PBS. ATC code: | |
Control | untreated whole blood sample |
Whole blood samples from healthy volunteers. |
glioma study 16 (LN-18) / normal astrocyte sample
Relative Expression (log2-ratio):1.7329664Number of Samples:2 / 3
Experimental | glioma study 16 (LN-18) |
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
glioma study 16 (LN-215) / normal astrocyte sample
Relative Expression (log2-ratio):1.6980934Number of Samples:2 / 3
Experimental | glioma study 16 (LN-215) |
Human glioma cell line LN215 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):1.6976452Number of Samples:4 / 4
Experimental | B-CLL study 11 (rolipram) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
Control | rolipram study 4 (normal B-cell; 20uM) |
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
glioma study 16 (LN-319) / normal astrocyte sample
Relative Expression (log2-ratio):1.6885061Number of Samples:2 / 3
Experimental | glioma study 16 (LN-319) |
Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
HIVGFP(G); SIVVLP(G) study 1 / HIVGFP(G) study 1
Relative Expression (log2-ratio):1.682087Number of Samples:2 / 2
Experimental | HIVGFP(G); SIVVLP(G) study 1 |
Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were infected with GFP-encoding HIV-1 pseudotyped with VSV-G [HIVGFP(G)] and VSV-G-pseudotyped SIVmac239 virus-like particles [SIVVLP(G)] for 48 hours. | |
Control | HIVGFP(G) study 1 |
Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were infected with GFP-encoding HIV-1 pseudotyped with VSV-G [HIVGFP(G)] for 48 hours. |
HIVGFP(G); SIVVLP(G) study 1 / uninfected monocyte-derived dendritic cell sample
Relative Expression (log2-ratio):1.6817684Number of Samples:2 / 2
Experimental | HIVGFP(G); SIVVLP(G) study 1 |
Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were infected with GFP-encoding HIV-1 pseudotyped with VSV-G [HIVGFP(G)] and VSV-G-pseudotyped SIVmac239 virus-like particles [SIVVLP(G)] for 48 hours. | |
Control | uninfected monocyte-derived dendritic cell sample |
Monocyte-derived dendritic cell samples (MDDC) from isolated and stimulated CD14+ monocytes (GM-CSF and IL-4 for dendritic cell differentiation) of adult peripheral blood. MDDC were treated with lipopolysaccharide (LPS) for 48 hours. |